U.S. Markets closed

U.S. FDA approves J&J's bladder cancer drug

April 12 (Reuters) - The U.S. Food and Drug Administration on Friday approved Johnson & Johnson's treatment for patients with a form of bladder cancer.

The green signal to the drug, Balversa, makes it the first approved treatment for bladder cancer that targets a genetic alteration known as FGFR3 or FGFR2, the FDA said. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)